Skip to main content

Advertisement

Log in

Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Malignant pleural mesothelioma (MPM) is considered a treatment-resistant disease. We determined the proportion of patients who received treatment in the last month of life and potential factors associated with use of chemotherapy at the end of life.

Methods

Consenting MPM patients compensated by the Dust Diseases Board (DDB) were included. Patient, treatment and outcome details were obtained through the DDB, treating physicians and Medicare Australia. The association between potential factors (age, gender, geographical location, disease stage, histological subtype, palliative care referral, length of first line chemotherapy and lines of treatment) and chemotherapy use in the last month of life was determined.

Results

A total of 147 MPM patients were included in the analysis: 78 received chemotherapy, 50 had radiotherapy and 116 had surgery (77 received more than one treatment modality whilst 56 received one treatment modality). Twenty-one patients received treatment in their last month of life: nine received chemotherapy; six, radiotherapy and six had surgery. Those who were treated with second or subsequent lines of chemotherapy were more at risk of receiving chemotherapy until the end of life (six of 19 patients, i.e., 32 %) compared to those who were only treated with first-line therapy (three of 59 patients, i.e., 5 %; p < 0.01). Patients who received chemotherapy at the end of life had shorter survival compared to those who did not receive chemotherapy at the end of life (5.3 vs. 12.5 months, respectively; p = 0.01).

Conclusions

Chemotherapy utilisation in the last month of life is not uncommon in this series of MPM patients. Patients who failed previous chemotherapy were more likely to receive chemotherapy near the end of life. More careful consideration of when to cease chemotherapy needs to be made as patients who received chemotherapy at the end of life had poorer survival outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644

    Article  PubMed  CAS  Google Scholar 

  2. van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Glaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889

    Article  PubMed  Google Scholar 

  3. McIllmurray M (2010) The medical treatment of cancer in palliative care. In: Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S, Portenov R (eds) Oxford textbook of palliative Medicine, 4th edn. Oxford University Press, New York, pp 513–525

    Google Scholar 

  4. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK, MS01 Trial Management Group (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371:1685–1694

    Article  PubMed  CAS  Google Scholar 

  5. Australia SW (2011) Mesothelioma in Australia: incidence 1982 to 2007, Mortality 1997 to 2007. Commonwealth of Australia, Canberra

    Google Scholar 

  6. Kao S, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N (2012) Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Intern Med J. doi:10.1111/j.1445-5994.2012.02925.x

  7. Fadul N, Elsayem A, Palmer JL, Zhang T, Braiteh F, Bruera E (2007) Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med 10:1146–1152

    Article  PubMed  Google Scholar 

  8. Kao S, Shafiq J, Vardy J, Adams D (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol 20:1555–1559

    Article  PubMed  CAS  Google Scholar 

  9. Nappa U, Lindqvist O, Rasmussen B, Axelsson B (2011) Palliative chemotherapy during the last month of life. Ann Oncol. doi:10.1093/annonc/mdq778

  10. Earle C, Neville B, Landrum M, Ayanian J, Block S, Weeks J (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321

    Article  PubMed  Google Scholar 

  11. Emanuel E, Young-Xu Y, Levinsky N, Gazelle G, Saynina O, Ash A (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643

    Article  PubMed  Google Scholar 

  12. Murillo JJ, Koeller J (2006) Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 11:1095–1099

    Article  PubMed  Google Scholar 

  13. Earle C, Park E, Lai B, Weeks J, Ayanian J, Block S (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21:1133–1138

    Article  PubMed  Google Scholar 

  14. Barbera L, Paszat L, Chartier C (2006) Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 22:12–17

    PubMed  Google Scholar 

  15. Kao S, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S (2012) Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. doi:10.1016/j.cllc.2012.03.011

  16. Australian Bureau of Statistics (2003) ASGC Remoteness Classification: purpose and use (Census Paper No. 03/01). Commonwealth of Australia, Canberra

    Google Scholar 

  17. Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, Musk AW (2004) A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 91:9–10

    Article  PubMed  CAS  Google Scholar 

  18. Boutin C, Rey F, Viallat J-R (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 108:754–758

    Article  PubMed  CAS  Google Scholar 

  19. O'Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 84:18–22

    Article  PubMed  Google Scholar 

  20. Zauderer MG, Sima CS, Ginsberg MS, Krug LM (2012) Lack of response to vinorelbine in patients with previously treated malignant pleural mesothleioma (MPM): rational for placebo-controlled trials in the 2nd line setting. 11th International Conference of the International Mesothelioma Interest Group, Boston, Abstr IB.7

    Google Scholar 

  21. Temel J, Greer J, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Piri WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742

    Article  PubMed  CAS  Google Scholar 

  22. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135:620–625

    Article  PubMed  Google Scholar 

  23. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866

    Article  PubMed  Google Scholar 

  24. Hawley R, Monk A (2004) Malignant mesothelioma: current practice and research directions. Collegian 11:22–26

    Article  Google Scholar 

Download references

Acknowledgments

This project was supported by a NSW DDB research grant. SC Kao is supported by a NHMRC scholarship and Cancer Institute NSW Research Scholar Award. J Vardy is supported by the Cancer Institute NSW. We would also like to thank the staff at the DDB including Kirsty Hannaford-Turner, Amanda Ellis and Giles Yates, who kindly assisted in the conduct of the study.

Conflict of interest

N van Zandwijk declares that he received consultancy fees and payment for lectures from Merck Serono and Eli Lilly. Other authors declared no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Janette Vardy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kao, S.C., van Zandwijk, N., Corte, P. et al. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Support Care Cancer 21, 1879–1884 (2013). https://doi.org/10.1007/s00520-013-1753-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-1753-3

Keywords

Navigation